The changing paradigm for the treatment of HER2-positive breast cancer

Aena Patel, Nisha Unni, Yan Peng

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


For decades, HER2-positive breast cancer was associated with poor outcomes and higher mortality rates than other breast cancer subtypes. However, the advent of Trastuzumab (Herceptin) has significantly changed the treatment paradigm of patients afflicted with HER2-positive breast cancer. The discovery of newer HER2-targeted therapies, such as Pertuzumab (Perjeta), has further added to the armamentarium of treating HER2-positive breast cancers. This review highlights recent advancements in the treatment of HER2-positive diseases, including the newer HER2-targeted therapies and immunotherapies in clinical trials, which have paved (and will further update) the way for clinical practice, and become part of the standard of care in the neoadjuvant, adjuvant or metastatic setting.

Original languageEnglish (US)
Article number2081
Pages (from-to)1-17
Number of pages17
Issue number8
StatePublished - Aug 2020


  • HER2-positive breast cancer
  • Immunotherapy
  • Metastatic disease
  • Neoadjuvant and adjuvant therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The changing paradigm for the treatment of HER2-positive breast cancer'. Together they form a unique fingerprint.

Cite this